Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 9/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | GAK | O14976 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851998 | 0.89 | SLC22A12 (0.56) | SLC22A12GAKEGFRESR2SLC22A6 | |
| SCHEMBL19643620 | 0.83 | GAK (0.44) | GAKESR2 | |
| SCHEMBL28544908 | 0.83 | ESR2 (0.47) | SLC22A12ESR2LMNASMN1; SMN2CA1 | |
| SCHEMBL8501623 | 0.83 | SMN1; SMN2 (0.50) | GAKCYP1A2HTTLMNASMN1; SMN2 | |
| SCHEMBL3551410 | 0.81 | HTR1A (0.46) | GAKLMNASYK | |
| SCHEMBL3576735 | 0.80 | KDR (0.40) | SLC22A12ESR2CYP1A2HTTSMN1; SMN2 | |
| SCHEMBL14999154 | 0.79 | SRC (0.39) | SLC22A12ESR2SMN1; SMN2 | |
| SCHEMBL371799 | 0.78 | PDGFRB (0.51) | — | |
| SCHEMBL28721905 | 0.77 | PTGS1 (0.36) | SLC22A12ESR2CA1CA2 | |
| SCHEMBL29397704 | 0.77 | PTGS1 (0.36) | SLC22A12ESR2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12171756-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| CN-111793060-B | NLRP3 modulators | 先天肿瘤免疫公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20220257587-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-08-18 | — | — | US | disclosed |
| US-11344543-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| CN-111793060-A | NLRP3 modulators | 先天肿瘤免疫公司 | 2020-10-20 | — | — | CN | disclosed |
| EP-3652166-A1 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20200129500-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2020-04-30 | — | — | US | disclosed |
| CN-110914258-A | NLRP3 modulators | 先天肿瘤免疫公司 | 2020-03-24 | — | — | CN | disclosed |
| WO-2019014402-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2019-01-17 | — | — | WO | disclosed |
| US-7511065-B2 | Mixed lineage kinase modulators | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511065-B2 | Mixed lineage kinase modulators | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511065-B2 | Mixed lineage kinase modulators | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| EP-1567528-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004048383-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129500-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | SLC22A12 1098/4885ALK 4810/4885GAK 3111/4885 |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDKL5, CDK15, CDK5 | SLC22A12 4600/4885ALK 3158/4885GAK 57/4885 |
| US-20220257587-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | SLC22A12 975/4885ALK 4834/4885GAK 3185/4885 |
| US-11344543-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | SLC22A12 1098/4885ALK 4810/4885GAK 3111/4885 |
| US-12171756-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | SLC22A12 975/4885ALK 4834/4885GAK 3185/4885 |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | MYLK2, CSNK1G2, CSNK1A1 | SLC22A12 3549/4885ALK 722/4885GAK 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.